Hyaluronan oligosaccharides perturb lymphocyte slow rolling on brain vascular endothelial cells: Implications for inflammatory demyelinating disease

Clayton W. Winkler, Scott C. Foster, Asako Itakura, Steven Matsumoto, Akira Asari, Owen McCarty, Lawrence (Larry) Sherman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Inflammatory demyelinating diseases like multiple sclerosis are characterized by mononuclear cell infiltration into the central nervous system. The glycosaminoglycan hyaluronan and its receptor, CD44, are implicated in the initiation and progression of a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). Digestion of hyaluronan tethered to brain vascular endothelial cells by a hyaluronidase blocks the slow rolling of lymphocytes along activated brain vascular endothelial cells and delays the onset of EAE. These effects could be due to the elimination of hyaluronan or the generation of hyaluronan digestion products that influence lymphocytes or endothelial cells. Here, we found that hyaluronan dodecasaccharides impaired activated lymphocyte slow rolling on brain vascular endothelial cells when applied to lymphocytes but not to the endothelial cells. The effects of hyaluronan dodecasaccharides on lymphocyte rolling were independent of CD44 and a receptor for degraded hyaluronan, Toll-like receptor-4. Subcutaneous injection of hyaluronan dodecasaccharides or tetrasaccharides delayed the onset of EAE in a manner similar to subcutaneous injection of hyaluronidase. Hyaluronan oligosaccharides can therefore act directly on lymphocytes to modulate the onset of inflammatory demyelinating disease.

Original languageEnglish (US)
Pages (from-to)160-168
Number of pages9
JournalMatrix Biology
Volume32
Issue number3-4
DOIs
StatePublished - Apr 24 2013

Fingerprint

Demyelinating Diseases
Hyaluronic Acid
Oligosaccharides
Endothelial Cells
Lymphocytes
Brain
Autoimmune Experimental Encephalomyelitis
CD44 Antigens
Hyaluronoglucosaminidase
Subcutaneous Injections
Multiple Sclerosis
Digestion
Toll-Like Receptor 4
Glycosaminoglycans
Central Nervous System

Keywords

  • CD44
  • Endothelial cell
  • Hyaluronan
  • Myelin
  • Toll-like receptor

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Hyaluronan oligosaccharides perturb lymphocyte slow rolling on brain vascular endothelial cells : Implications for inflammatory demyelinating disease. / Winkler, Clayton W.; Foster, Scott C.; Itakura, Asako; Matsumoto, Steven; Asari, Akira; McCarty, Owen; Sherman, Lawrence (Larry).

In: Matrix Biology, Vol. 32, No. 3-4, 24.04.2013, p. 160-168.

Research output: Contribution to journalArticle

@article{9d0586fefe67472395ede33743618d7f,
title = "Hyaluronan oligosaccharides perturb lymphocyte slow rolling on brain vascular endothelial cells: Implications for inflammatory demyelinating disease",
abstract = "Inflammatory demyelinating diseases like multiple sclerosis are characterized by mononuclear cell infiltration into the central nervous system. The glycosaminoglycan hyaluronan and its receptor, CD44, are implicated in the initiation and progression of a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). Digestion of hyaluronan tethered to brain vascular endothelial cells by a hyaluronidase blocks the slow rolling of lymphocytes along activated brain vascular endothelial cells and delays the onset of EAE. These effects could be due to the elimination of hyaluronan or the generation of hyaluronan digestion products that influence lymphocytes or endothelial cells. Here, we found that hyaluronan dodecasaccharides impaired activated lymphocyte slow rolling on brain vascular endothelial cells when applied to lymphocytes but not to the endothelial cells. The effects of hyaluronan dodecasaccharides on lymphocyte rolling were independent of CD44 and a receptor for degraded hyaluronan, Toll-like receptor-4. Subcutaneous injection of hyaluronan dodecasaccharides or tetrasaccharides delayed the onset of EAE in a manner similar to subcutaneous injection of hyaluronidase. Hyaluronan oligosaccharides can therefore act directly on lymphocytes to modulate the onset of inflammatory demyelinating disease.",
keywords = "CD44, Endothelial cell, Hyaluronan, Myelin, Toll-like receptor",
author = "Winkler, {Clayton W.} and Foster, {Scott C.} and Asako Itakura and Steven Matsumoto and Akira Asari and Owen McCarty and Sherman, {Lawrence (Larry)}",
year = "2013",
month = "4",
day = "24",
doi = "10.1016/j.matbio.2013.01.002",
language = "English (US)",
volume = "32",
pages = "160--168",
journal = "Matrix Biology",
issn = "0945-053X",
publisher = "Elsevier",
number = "3-4",

}

TY - JOUR

T1 - Hyaluronan oligosaccharides perturb lymphocyte slow rolling on brain vascular endothelial cells

T2 - Implications for inflammatory demyelinating disease

AU - Winkler, Clayton W.

AU - Foster, Scott C.

AU - Itakura, Asako

AU - Matsumoto, Steven

AU - Asari, Akira

AU - McCarty, Owen

AU - Sherman, Lawrence (Larry)

PY - 2013/4/24

Y1 - 2013/4/24

N2 - Inflammatory demyelinating diseases like multiple sclerosis are characterized by mononuclear cell infiltration into the central nervous system. The glycosaminoglycan hyaluronan and its receptor, CD44, are implicated in the initiation and progression of a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). Digestion of hyaluronan tethered to brain vascular endothelial cells by a hyaluronidase blocks the slow rolling of lymphocytes along activated brain vascular endothelial cells and delays the onset of EAE. These effects could be due to the elimination of hyaluronan or the generation of hyaluronan digestion products that influence lymphocytes or endothelial cells. Here, we found that hyaluronan dodecasaccharides impaired activated lymphocyte slow rolling on brain vascular endothelial cells when applied to lymphocytes but not to the endothelial cells. The effects of hyaluronan dodecasaccharides on lymphocyte rolling were independent of CD44 and a receptor for degraded hyaluronan, Toll-like receptor-4. Subcutaneous injection of hyaluronan dodecasaccharides or tetrasaccharides delayed the onset of EAE in a manner similar to subcutaneous injection of hyaluronidase. Hyaluronan oligosaccharides can therefore act directly on lymphocytes to modulate the onset of inflammatory demyelinating disease.

AB - Inflammatory demyelinating diseases like multiple sclerosis are characterized by mononuclear cell infiltration into the central nervous system. The glycosaminoglycan hyaluronan and its receptor, CD44, are implicated in the initiation and progression of a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). Digestion of hyaluronan tethered to brain vascular endothelial cells by a hyaluronidase blocks the slow rolling of lymphocytes along activated brain vascular endothelial cells and delays the onset of EAE. These effects could be due to the elimination of hyaluronan or the generation of hyaluronan digestion products that influence lymphocytes or endothelial cells. Here, we found that hyaluronan dodecasaccharides impaired activated lymphocyte slow rolling on brain vascular endothelial cells when applied to lymphocytes but not to the endothelial cells. The effects of hyaluronan dodecasaccharides on lymphocyte rolling were independent of CD44 and a receptor for degraded hyaluronan, Toll-like receptor-4. Subcutaneous injection of hyaluronan dodecasaccharides or tetrasaccharides delayed the onset of EAE in a manner similar to subcutaneous injection of hyaluronidase. Hyaluronan oligosaccharides can therefore act directly on lymphocytes to modulate the onset of inflammatory demyelinating disease.

KW - CD44

KW - Endothelial cell

KW - Hyaluronan

KW - Myelin

KW - Toll-like receptor

UR - http://www.scopus.com/inward/record.url?scp=84876847258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876847258&partnerID=8YFLogxK

U2 - 10.1016/j.matbio.2013.01.002

DO - 10.1016/j.matbio.2013.01.002

M3 - Article

C2 - 23333375

AN - SCOPUS:84876847258

VL - 32

SP - 160

EP - 168

JO - Matrix Biology

JF - Matrix Biology

SN - 0945-053X

IS - 3-4

ER -